Bupropion in the Treatment of Pathological Gambling

Pathological Gambling Clinical Trial

Official title:

Bupropion Versus Placebo in the Treatment of Pathological Gambling

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00055393
• Other study ID #: 200007038
• Secondary ID: R21MH063289DSIR
• Status: Completed
• Phase: N/A
• First received: February 28, 2003
• Last updated: March 10, 2017
• Start date: July 2002
• Est. completion date: April 2006

Study information

• Verified date: March 2017
• Source: University of Iowa
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will determine whether the drug bupropion is an effective treatment for Pathological Gambling.

Description:

As gambling opportunities proliferate, PG has become a major health concern. Despite its importance, few treatment options with proven efficacy exist. This study will attempt to identify an effective treatment for PG.

Participants are randomly assigned to receive either bupropion or placebo for 12 weeks. Participants are assessed at baseline and at Weeks 2, 3, 4, 5, 6, 8, 10, and 12. Self administered questionnaires and interviews are used to assess participants. Follow-up assessments are made 1, 3, and 6 months after study completion.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: April 2006
• Est. primary completion date: May 2005
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Meet the criteria for Pathological Gambling (DSM-IV-TR), through the administration of the National Opinion Research Center DSM Screen for Gambling Problems(NODS);

• Meet the criteria for Pathological Gambling (DSM-IV-TR), through the administration of the National Opinion Research Center DSM Screen for Gambling Problems(NODS);

• Receive a score of 5 or more on the South Oaks Gambling Screen (SOGS);

• Have PG for at least one year;

• Have had at least 2 or more gambling episodes during the 2-week screening period;

• Speak standard English;

• Be able to give written informed consent.

Exclusion Criteria:

• Evidence of current (past 3 months) substance misuse;

• Had a Hamilton Depression Rating Scale (HDRS)27 score of 18 or more (or a score on item 1 of greater than 2;

• Had a current eating disorder (except binge eating disorder);

• Had any history of seizures, or suicidal or aggressive behavior;

• Had a urine drug screen positive for stimulants, opiates, hallucinogens, or phencyclidine;

• Had a current or past psychotic disorder, bipolar disorder, or significant cognitive disorder;

• Received monoamine oxidase inhibitors within 3 weeks of randomization, long acting phenothiazine within 3 months of randomization,fluoxetine within 4 weeks of randomization, or other psychotropic drugs within 2 weeks of randomization;

• Had prior exposure to bupropion;

• Were engaged in individual, group, or couples psychotherapy during the 2 weeks before randomization, (except Gamblers Anonymous).

Related Conditions & MeSH terms

• Gambling
• Pathological Gambling

Intervention

Drug:
• Bupropion
18 subjects in this randomly controlled double blind study received bupropion.
• Placebo
21 subjects received Placebo.

Locations

Country	Name	City	State
United States	Roy J. and Lucille A. Carver College of Medicine, University of Iowa	Iowa City	Iowa

Sponsors (2)

Lead Sponsor	Collaborator
University of Iowa	National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Black DW, Arndt S, Coryell WH, Argo T, Forbush KT, Shaw MC, Perry P, Allen J. Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study. J Clin Psychopharmacol. 2007 Apr;27(2):143-50. — View Citation